Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07777120 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07777120 · ClinicalTrials.gov record · last posted 2026-08-20

Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma

Name: Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma — clinical trial record (NCT07777120)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhaseNot specified

SponsorBristol-Myers Squibb

Started2026-03-24

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This non-interventional study will use information already reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) registry during routine clinical care. The study will assess the long-term safety and effectiveness of lisocabtagene maraleucel in participants with relapsed/refractory marginal zone lymphoma.

Trial Details

NCT Number	NCT07777120
Lead Sponsor	Bristol-Myers Squibb
Conditions	Marginal Zone Lymphoma
Enrollment	300 participants
Start Date	2026-03-24
Primary Completion	2048-03-31 (estimated)
Study Completion	2048-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-20